Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Jenner

Showing results (121-130 of 177) with videos related to

Pageof 18
Sort By:
Behavioural Pharmacology|January 13, 2012
Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned ratKayhan A Tayarani-Binazir, Michael J Jackson, Isobel Strang, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|April 11, 2008
Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systemsNicholas MacInnes, Mahmoud M Iravani, Elaine Perry, et al.
Neurobiology of Disease|August 18, 2010
Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesiaBai-Yun Zeng, Mahmoud M Iravani, Michael J Jackson, et al.
European Journal of Pharmacology|March 23, 2010
The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmosetKayhan A Tayarani-Binazir, Michael J Jackson, Ria Fisher, et al.
The European Journal of Neuroscience|March 25, 2005
A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosetsMahmoud M Iravani, Emilie Syed, Michael J Jackson, et al.
International Review of Neurobiology|August 14, 2017
Nonmotor Symptoms in Experimental Models of Parkinson's DiseaseNataliya Titova, Anthony H V Schapira, K Ray Chaudhuri, et al.
NPJ Parkinson'S Disease|July 21, 2017
Non-oral dopaminergic therapies for Parkinson's disease: current treatments and the futureK Ray Chaudhuri, Mubasher A Qamar, Thadshani Rajah, et al.
European Journal of Pharmacology|December 16, 2014
The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosetsShin-ichi Uchida, Kazuhiro Soshiroda, Eri Okita, et al.
European Journal of Pharmacology|August 24, 2006
The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosetsSarah Rose, Michael J Jackson, Lance A Smith, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 5, 2002
Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopaMikko Kuoppamäki, Ghassan Al-Barghouthy, Michael Jackson, et al.
Pageof 18

Showing results (121-130 of 177) with videos related to

Sort By:
Pageof 18
Behavioural Pharmacology|January 13, 2012
Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned ratKayhan A Tayarani-Binazir, Michael J Jackson, Isobel Strang, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|April 11, 2008
Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systemsNicholas MacInnes, Mahmoud M Iravani, Elaine Perry, et al.
Neurobiology of Disease|August 18, 2010
Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesiaBai-Yun Zeng, Mahmoud M Iravani, Michael J Jackson, et al.
European Journal of Pharmacology|March 23, 2010
The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmosetKayhan A Tayarani-Binazir, Michael J Jackson, Ria Fisher, et al.
The European Journal of Neuroscience|March 25, 2005
A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosetsMahmoud M Iravani, Emilie Syed, Michael J Jackson, et al.
International Review of Neurobiology|August 14, 2017
Nonmotor Symptoms in Experimental Models of Parkinson's DiseaseNataliya Titova, Anthony H V Schapira, K Ray Chaudhuri, et al.
NPJ Parkinson'S Disease|July 21, 2017
Non-oral dopaminergic therapies for Parkinson's disease: current treatments and the futureK Ray Chaudhuri, Mubasher A Qamar, Thadshani Rajah, et al.
European Journal of Pharmacology|December 16, 2014
The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosetsShin-ichi Uchida, Kazuhiro Soshiroda, Eri Okita, et al.
European Journal of Pharmacology|August 24, 2006
The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosetsSarah Rose, Michael J Jackson, Lance A Smith, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 5, 2002
Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopaMikko Kuoppamäki, Ghassan Al-Barghouthy, Michael Jackson, et al.
Pageof 18